JAGX (Jaguar Health, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by JAGX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-12 | JOHN MICEK | Director | A | — | — |
| 2026-01-21 | Steven R. King | See Remarks | A | — | — |
| 2026-01-21 | LISA A CONTE | See Remarks | A | — | — |
| 2026-01-21 | Jonathan S. Wolin | See Remarks | A | — | — |
| 2025-12-15 | Jonathan B. Siegel | Director | A | — | — |
| 2025-12-15 | Anula Jayasuriya | Director | A | — | — |
| 2025-12-15 | Carol R. Lizak | Chief Financial Officer | A | — | — |
| 2025-12-15 | Pravin R Chaturvedi | Chief Scientific Officer | A | — | — |
| 2025-12-15 | JAMES J BOCHNOWSKI | Director | A | — | — |
| 2025-06-26 | Steven R. King | See Remarks | MIXED | — | — |
| 2025-06-26 | JAMES J BOCHNOWSKI | Director | MIXED | — | — |
| 2025-06-26 | Jonathan S. Wolin | See Remarks | MIXED | — | — |
| 2025-06-26 | JOHN MICEK | Director | MIXED | — | — |
| 2025-06-26 | Jonathan B. Siegel | Director | MIXED | — | — |
| 2025-06-26 | LISA A CONTE | CEO and President | MIXED | — | — |
| 2025-06-26 | Pravin R Chaturvedi | Chief Scientific Officer | MIXED | — | — |
| 2025-05-20 | LISA A CONTE | CEO and President | M | — | — |
| 2025-05-20 | Steven R. King | See Remarks | M | — | — |
| 2025-04-02 | Carol R. Lizak | Chief Financial Officer | Buy | — | — |
| 2025-04-02 | Steven R. King | See Remarks | Buy | — | — |
| 2025-04-02 | Pravin R Chaturvedi | Chief Scientific Officer | Buy | — | — |
| 2025-04-02 | JOHN MICEK | Director | Buy | — | — |
| 2025-04-02 | LISA A CONTE | CEO and President | Buy | — | — |
| 2025-04-02 | JAMES J BOCHNOWSKI | Director | Buy | — | — |
| 2025-04-02 | Jonathan S. Wolin | See Remarks | Buy | — | — |
| 2025-04-02 | Jonathan B. Siegel | Director | Buy | — | — |
| 2024-10-10 | JOHN MICEK | Director | A | — | — |
| 2024-10-10 | Anula Jayasuriya | Director | A | — | — |
| 2024-10-10 | Pravin R Chaturvedi | Chief Scientific Officer | A | — | — |
| 2024-10-10 | JAMES J BOCHNOWSKI | Director | A | — | — |
| 2024-10-10 | Jonathan B. Siegel | Director | A | — | — |
| 2024-10-10 | Steven R. King | See Remarks | A | — | — |
| 2024-10-10 | Carol R. Lizak | Chief Financial Officer | A | — | — |
| 2024-10-10 | LISA A CONTE | See Remarks | A | — | — |
| 2024-10-10 | Jonathan S. Wolin | See Remarks | A | — | — |
| 2024-05-21 | Steven R. King | See Remarks | M | — | — |
| 2024-05-21 | LISA A CONTE | CEO and President | M | — | — |
| 2024-05-21 | Carol R. Lizak | Chief Financial Officer | M | — | — |
| 2024-05-21 | Jonathan S. Wolin | Chief of Staff, CCO & GC | M | — | — |
| 2024-05-21 | Pravin R Chaturvedi | Chief Scientific Officer | M | — | — |
| 2024-04-17 | Jonathan S. Wolin | Chief of Staff, CCO & GC | M | — | — |
| 2024-04-17 | LISA A CONTE | CEO and President | M | — | — |
| 2024-04-17 | Pravin R Chaturvedi | Chief Scientific Officer | M | — | — |
| 2024-04-17 | Carol R. Lizak | Chief Financial Officer | M | — | — |
| 2024-04-17 | Steven R. King | See Remarks | M | — | — |
| 2023-08-14 | Jonathan S. Wolin | Chief of Staff, CCO & GC | A | — | — |
| 2023-08-14 | Carol R. Lizak | Chief Financial Officer | A | — | — |
| 2023-08-14 | JAMES J BOCHNOWSKI | Director | A | — | — |
| 2023-08-14 | JOHN MICEK | Director | A | — | — |
| 2023-08-14 | Steven R. King | see remarks | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | See Remarks | 920 | — |
| — | See Remarks | 375 | — |
| — | Chief Scientific Officer | 375 | — |
| — | See Remarks | 374 | — |
| — | Chief Financial Officer | 374 | — |
| — | Director | 233 | — |
| — | Director | 212 | — |
| — | Director | 202 | — |
| — | Director | 186 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the JAGX quote page; the site-wide leaderboard is on the insider transactions hub.